

29 May 2015

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2014/15 Invitation to Tender, dated 6 November 2014.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2014/15 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2018

CORRECTION to April 2015 tender notification: in bold and strikethrough

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Zopiclone ¹	Tab 7.5 mg; 500 tablet, blister bottle pack	\$11.90	\$8.99	Zopiclone Actavis (Actavis)	1 October 2015	1 December 2015	1 March 2016	Apo-Zopiclone (Apotex)
1. Brand switch fee of \$4.33 is payable for this product from 1 March 2016 until 1 June 2016								

CORRECTION to April 2015 tender notification: in bold and strikethrough

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Pack Price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Zopiclone	Tab 7.5 mg; 500 tablet, blister bottle pack	\$11.90 \$8.99	Zopiclone Actavis (Actavis)	1%	1 October 2015	1 December 2015

2014/15 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2018

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Pancreatic enzyme	Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease; 100 capsule, bottle pack	\$94.38	\$94.38	Creon 25000 (Abbott)	1 August 2015	1 November 2015
Pancreatic enzyme	Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease; 100 capsule, bottle pack	\$34.93	\$34.93	Creon 10000 (Abbott)	1 August 2015	1 November 2015
Paracetamol	Suppos 500 mg; 50 suppositories	\$20.70	\$12.60	Paracare (API)	1 September 2015	1 December 2015
Sodium cromoglycate	Eye drops 2%; 5 ml OP	\$1.18	\$0.85	Rexacrom (Rex Medical)	1 September 2015	1 December 2015

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Acetylcysteine ¹	Inj 200 mg per ml, 10 ml ampoule; 10 ampoules	\$178.00	\$78.34	DBL Acetylcysteine (Hospira)	1 July 2015	1 September 2015	1 December 2015	Martindale Acetylcysteine (Max Health)

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
								Acetadote (AFT)
Bosentan	Tab 62.5 mg; 56 tablet, blister pack	\$1,500.00 per 60 tablets, and \$4,585.00 per 60 tablets	\$375.00 per 56 tablets	Mylan-Bosentan (Mylan)	1 August 2015	1 December 2015	1 March 2016	Pms-Bosentan (AFT) Tracleer (Actelion)
Bosentan	Tab 125 mg; 56 tablet, blister pack	\$1,500.00 per 60 tablets, and \$4,585.00 per 60 tablets	\$375.00 per 56 tablets	Mylan-Bosentan (Mylan)	1 August 2015	1 December 2015	1 March 2016	Pms-Bosentan (AFT) Tracleer (Actelion)
Chlorhexidine gluconate	Soln 4% wash; 500 ml	\$5.90	\$3.98	healthE (Jaychem)	1 August 2015	1 October 2015	1 January 2016	Orion (Orion)
Citalopram hydrobromide ²	Tab 20 mg; 84 tablet, blister pack	\$2.34	\$1.79	PSM Citalopram (API)	1 October 2015	1 December 2015	1 March 2016	Arrow-Citalopram (Actavis)
Cyclizine hydrochloride	Tab 50 mg; 20 tablet, blister pack	\$0.59 per 10 tablets	\$0.59 per 20 tablets	Nauzene (Actavis)	1 November 2015	1 January 2016	1 April 2016	Nausicalm (AFT)
Desferrioxamine mesilate	Inj 500 mg vial; 10 vials	\$109.89	\$51.52	Desferal (Novartis)	1 December 2015	1 February 2016	1 May 2016	Hospira (Hospira)
Dexamethasone ³	Tab 0.5 mg; 30 tablet, bottle pack	\$5.87 per 100 tablets of tab 1 mg	\$0.88 per 30 tablets of tab 0.5 mg	Dexamethsone (Aspen)	1 November 2015	1 January 2016	1 April 2016	Douglas (Douglas)
Dexamethasone	Tab 4 mg; 30 tablet, bottle pack	\$8.16 per 100 tablets	\$1.84 per 30 tablets	Dexamethsone (Aspen)	1 November 2015	1 January 2016	1 April 2016	Douglas (Douglas)
Lansoprazole	Cap 15 mg;	\$2.00 per 28	\$5.08 per	Lanzol Relief	1 November 2015	1 January 2016	1 April 2016	Solox

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
	100 capsule, bottle pack	capsules	100 capsules	(Mylan)				(Douglas)
Lansoprazole	Cap 30 mg; 100 capsule, bottle pack	\$2.32 per 28 capsules	\$5.93 per 100 capsules	Lanzol Relief (Mylan)	1 November 2015	1 January 2016	1 April 2016	Solox (Douglas)
Metformin hydrochloride	Tab immediate- release 850 mg; 500 tablet, bottle pack	\$10.10	\$7.82	Metformin Mylan (Mylan)	1 October 2015	1 December 2015	1 March 2016	Apotex (Apotex)
Oil in water emulsion	Crn; 500 g	\$2.63	\$2.25	O/W Fatty Emulsion Cream (Boucher)	1 November 2015	1 January 2016	1 April 2016	healthE Fatty Cream (Jaychem)
Paracetamol	Suppos 125 mg; 10 suppositories	\$7.49 per 20 suppositories	\$3.69 per 10 suppositori es	Gacet (AFT)	1 October 2015	1 December 2015	1 March 2016	Panadol (GSK)
Paracetamol	Suppos 250 mg; 10 suppositories	\$14.40 per 20 suppositories	\$3.79 per 10 suppositori es	Gacet (AFT)	1 October 2015	1 December 2015	1 March 2016	Panadol (GSK)
Pioglitazone	Tab 15 mg; 90 tablet, bottle pack	\$1.50 per 28 tablets	\$3.47 per 90 tablets	Vexazone (Mylan)	1 October 2015	1 December 2015	1 March 2016	Pizaccord (Douglas)
Pioglitazone	Tab 30 mg; 90 tablet, bottle pack	\$2.50 per 28 tablets	\$5.06 per 90 tablets	Vexazone (Mylan)	1 October 2015	1 December 2015	1 March 2016	Pizaccord (Douglas)
Pioglitazone	Tab 45 mg; 90 tablet, bottle pack	\$3.50 per 28 tablets	\$7.10 per 90 tablets	Vexazone (Mylan)	1 October 2015	1 December 2015	1 March 2016	Pizaccord (Douglas)

1. Acetylcysteine inj 200 mg per ml, 30 ml will have a subsidy reduction from 1 September 2015 and will be delisted from Section B from 1 December 2015.

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
2. Brand switch fee of \$4.33 is payable for this product from 1 March 2016 until 1 June 2016.								
3. Dexamethasone tab 1 mg to be delisted 1 April 2016.								

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Carmustine	Inj 100 mg vial; 1 vial	\$532.00	\$532.00	BiCNU (Actavis)	1%	1 July 2015	1 September 2015
Flumazenil	Inj 0.1 mg per ml, 5 ml ampoule; 5 ampoules	\$170.10	\$85.05	Anexate (Roche)	1%	1 July 2015	1 September 2015
Fluorouracil ¹	Inj 50 mg per ml, 20 ml vial; 1 vial	\$7.50	\$10.00	Fluorouracil Ebewe (Sandoz)	1%	1 August 2015	1 October 2015
Fluorouracil ¹	Inj 50 mg per ml, 50 ml vial; 1 vial	\$18.00	\$17.00	Fluorouracil Ebewe (Sandoz)	1%	1 August 2015	1 October 2015
Fluorouracil ¹	Inj 50 mg per ml, 100 ml vial; 1 vial	\$34.50	\$30.00	Fluorouracil Ebewe (Sandoz)	1%	1 August 2015	1 October 2015
Irinotecan hydrochloride ²	Inj 20 mg per ml, 2 ml vial; 1 vial	\$9.34	\$11.50	Irinotecan Actavis 40 (Actavis)	1%	1 July 2015	1 September 2015
Irinotecan hydrochloride ²	Inj 20 mg per ml, 5 ml vial; 1 vial	\$23.34	\$17.80	Irinotecan Actavis 100 (Actavis)	1%	1 July 2015	1 September 2015
Mitozantrone ³	Inj 2 mg per ml, 10 ml vial; 1 vial	\$100.00	\$97.50	Mitozantrone Ebewe (Sandoz)	1%	1 July 2015	1 September 2015

Chemical Name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Paracetamol	Suppos 500 mg; 50 suppositories	\$20.70	\$12.60	Paracare (API)	1%	1 September 2015	1 November 2015
Tranexamic acid	Inj 100 mg per ml, 5 ml ampoule; 10 ampoules	\$124.73	\$55.00	Cyklokapron (Pfizer)	1%	1 July 2015	1 September 2015
<p>1. The price and subsidy of fluorouracil (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 August 2015. The subsidy for fluorouracil inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$0.77 per 100 mg to \$0.66 per 100 mg from 1 August 2015. Fluorouracil Ebewe inj 50 mg per ml, 10 ml vial to be delisted from Section H from 1 October 2015.</p> <p>2. The price and subsidy of irinotecan hydrochloride (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2015. The subsidy for irinotecan hydrochloride inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$0.24 per 1 mg to \$0.19 per 1 mg from 1 July 2015.</p> <p>3. The price and subsidy of mitozantrone (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 July 2015. The subsidy for mitozantrone inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$5.65 per 1 mg to \$5.51 per 1 mg from 1 July 2015. Mitozantrone Ebewe inj 2 mg per ml, 5 ml vial and Onkotrone inj 2 mg per ml, 12.5 ml vial to be delisted from 1 January 2016.</p>							

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by reference pricing and delisting
Acetylcysteine ¹	Inj 200 mg per ml, 10 ml ampoule; 10 ampoules	\$178.00	\$78.34	DBL Acetylcysteine (Hospira)	1%	1 July 2015	1 September 2015	Martindale Acetylcysteine (Max Health) Acetadote (AFT)
Aciclovir	Inj 250 mg vial; 5 vials	\$14.09	\$10.10	Aciclovir-Claris (AFT)	1%	1 November 2015	1 January 2016	Zovirax IV (GSK)
Bosentan	Tab 62.5 mg; 56 tablet, blister pack	\$1,500.00 per 60 tablets, and	\$375.00 per 56 tablets	Mylan-Bosentan (Mylan)	1%	1 August 2015	1 December 2015	Pms-Bosentan (AFT) Tracleer

Chemical Name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by reference pricing and delisting
		\$4,585.00 per 60 tablets						(Actelion)
Bosentan	Tab 125 mg; 56 tablet, blister pack	\$1,500.00 per 60 tablets, and \$4,585.00 per 60 tablets	\$375.00 per 56 tablets	Mylan-Bosentan (Mylan)	1%	1 August 2015	1 December 2015	Pms-Bosentan (AFT) Tracleer (Actelion)
Carboplatin ²	Inj 10 mg per ml, 5 ml vial; 1 vial	\$20.00	\$15.07	DBL Carboplatin (Hospira)	1%	1 July 2015	1 September 2015	Carboplatin Ebewe (Sandoz)
Carboplatin ²	Inj 10 mg per ml, 15 ml vial; 1 vial	\$19.50	\$14.05	DBL Carboplatin (Hospira)	1%	1 July 2015	1 September 2015	Carbaccord (Actavis)
Carboplatin ²	Inj 10 mg per ml, 45 ml vial; 1 vial	\$48.50	\$32.59	DBL Carboplatin (Hospira)	1%	1 July 2015	1 September 2015	Carbaccord (Actavis)
Cefepime hydrochloride	Inj 1 g vial; 1 vial	\$8.80	\$3.95	Cefepime-AFT (AFT)	1%	1 August 2015	1 October 2015	DBL Cefepime (Hospira)
Cefepime hydrochloride	Inj 2 g vial; 1 vial	\$17.60	\$6.92	Cefepime-AFT (AFT)	1%	1 August 2015	1 October 2015	DBL Cefepime (Hospira)
Cefoxitin sodium	Inj 1 g vial; 10 vial	\$74.25 for 5 vials	\$58.00 for 10 vials	Cefoxitin Actavis (Actavis)	1%	1 November 2015	1 January 2016	Hospira (Hospira)
Citalopram hydrobromide	Tab 20 mg; 84 tablet, blister pack	\$2.34	\$1.79	PSM Citalopram (API)	1%	1 October 2015	1 December 2015	Arrow- Citalopram (Actavis)
Cyclizine hydrochloride	Tab 50 mg; 20 tablet, blister pack	\$0.59 per 10 tablets	\$0.59 per 20 tablets	Nauzene (Actavis)	1%	1 November 2015	1 January 2016	Nausicalm (AFT)

Chemical Name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by reference pricing and delisting
Desferrioxamine mesilate	Inj 500 mg vial; 10 vials	\$109.89	\$51.52	Desferal (Novartis)	1%	1 December 2015	1 February 2016	Hospira (Hospira)
Dexamethasone ⁴	Tab 0.5 mg; 30 tablet, bottle pack	\$5.87 per 100 tablets of tab 1 mg	\$0.88 per 30 tablets of 0.5 mg	Dexmethsone (Aspen)	1%	1 November 2015	1 January 2016	Douglas (Douglas)
Dexamethasone	Tab 4 mg; 30 tablet, bottle pack	\$8.16 per 100 tablets	\$1.84 per 30 tablets	Dexmethsone (Aspen)	1%	1 November 2015	1 January 2016	Douglas (Douglas)
Dopamine hydrochloride	Inj 40 mg per ml, 5 ml ampoule; 5 ampoules	\$69.77 per 10 ampoules	\$16.89 per 5 ampoules	DBL Sterile Dopamine Concentrate (Hospira)	1%	1 July 2015	1 September 2015	Martindale (Max Health)
Doxorubicin hydrochloride ³	Inj 2 mg per ml, 25 ml; 1 vial	\$17.00	\$11.50	Doxorubicin Ebewe (Sandoz)	1%	1 December 2015	1 February 2016	Arrow- Doxorubicin (Actavis)
Doxorubicin hydrochloride ³	Inj 2 mg per ml, 100 ml vial; 1 vial	\$65.00	\$46.00	Doxorubicin Ebewe (Sandoz)	1%	1 December 2015	1 February 2016	Arrow- Doxorubicin (Actavis)
Lansoprazole	Cap 15 mg; 100 capsule, bottle pack	\$2.00 per 28 capsule s	\$5.08 per 100 capsule s	Lanzol Relief (Mylan)	1%	1 November 2015	1 January 2016	Solox (Douglas)
Lansoprazole	Cap 30 mg; 100 capsule, bottle pack	\$2.32 per 28 capsule s	\$5.93 per 100 capsule s	Lanzol Relief (Mylan)	1%	1 November 2015	1 January 2016	Solox (Douglas)
Metformin hydrochloride	Tab immediate-release 850 mg; 500 tablet, bottle pack	\$10.10	\$7.82	Metformin Mylan (Mylan)	1%	1 October 2015	1 December 2015	Apotex (Apotex)
Paracetamol	Suppos 125 mg; 10 suppositories	\$7.49 per 20 suppositories	\$3.69 per 10 suppositorie	Gacet (AFT)	1%	1 October 2015	1 December 2015	Panadol (GSK)

Chemical Name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by reference pricing and delisting
			s					
Paracetamol	Suppos 250 mg; 10 suppositories	\$14.40 per 20 suppositories	\$3.79 per 10 suppositories	Gacet (AFT)	1%	1 October 2015	1 December 2015	Panadol (GSK)
Pioglitazone	Tab 15 mg; 90 tablet, bottle pack	\$1.50 per 28 tablets	\$3.47 per 90 tablets	Vexazone (Mylan)	1%	1 October 2015	1 December 2015	Pizaccord (Douglas)
Pioglitazone	Tab 30 mg; 90 tablet, bottle pack	\$2.50 per 28 tablets	\$5.06 per 90 tablets	Vexazone (Mylan)	1%	1 October 2015	1 December 2015	Pizaccord (Douglas)
Pioglitazone	Tab 45 mg; 90 tablet, bottle pack	\$3.50 per 28 tablets	\$7.10 per 90 tablets	Vexazone (Mylan)	1%	1 October 2015	1 December 2015	Pizaccord (Douglas)

1. Acetylcysteine inj 200 mg per ml, 30 ml to be delisted from Section H from 1 September 2015.
2. Hospira's brand of carboplatin (PCT only – Specialist) will be listed in Section B of the Pharmaceutical Schedule from 1 July 2015. The subsidy for carboplatin inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$0.13 per 1 mg to \$0.08 per 1 mg from 1 September 2015. Carboplatin Ebewe inj 10 mg per ml, 100 ml vial to be delisted from Section H from 1 September 2015.
3. The price and subsidy of doxorubicin hydrochloride (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 December 2015. The subsidy for doxorubicin hydrochloride inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$0.37 per 1 mg to \$0.25 per 1 mg from 1 February 2016. Doxorubicin hydrochloride inj 50 mg vial to be delisted from Section H from 1 February 2016.
4. Dexamethasone tab 1 mg to be delisted 1 January 2016.

7. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Pack Price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Dobutamine hydrochloride	Inj 12.5 mg per ml, 20 ml ampoule; 5 ampoules	\$24.45	Dobutamine-Claris (AFT)	1%	1 November 2015	1 January 2016
Daptomycin	Inj 350 mg vial; 1 vial	\$175.16	Cubicin (Novartis)	1%	1 July 2015	1 September 2015
Daptomycin	Inj 500 mg vial;	\$243.52	Cubicin	1%	1 July 2015	1 September 2015

Chemical name	Presentation; Pack size and type	Pack Price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
	1 vial		(Novartis)			
Doxorubicin hydrochloride ¹	Inj 2 mg per ml, 50 ml vial; 1 vial	\$23.00	Doxorubicin Ebewe (Sandoz)	1%	1 December 2015	1 February 2016
Linezolid	Inj 2 mg per ml, 300 ml bag; 10 bags	\$1,650.00	Zyvox (Pfizer)	1%	1 July 2015	1 September 2015
Linezolid	Oral liq 20 mg per ml; 150 ml	\$775.00	Zyvox (Pfizer)	1%	1 July 2015	1 September 2015
Linezolid	Tab 600 mg; 10 tablet, blister pack	\$800.00	Zyvox (Pfizer)	1%	1 July 2015	1 September 2015
Pancreatic enzyme	Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease; 100 capsule, bottle pack	\$94.38	Creon 25000 (Abbott)	1%	1 August 2015	1 October 2015
Pancreatic enzyme	Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease; 100 capsule, bottle pack	\$34.93	Creon 10000 (Abbott)	1%	1 August 2015	1 October 2015
<p>1. The price and subsidy of doxorubicin hydrochloride (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 December 2015. The subsidy for doxorubicin hydrochloride inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$0.37 per 1 mg to \$0.25 per 1 mg from 1 February 2016.</p>						

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 7 November 2013, and the 2014/15 Invitation to Tender, dated 6 November 2014:

2013/14 Invitation to Tender

Chemical Name	Line Item	Chemical Name	Line Item
Brinzolamide	Eye Drops 1%	Sodium chloride	Soln 0.9% for irrigation, 30 ml
Cetirizine hydrochloride	Tab 10 mg	Travoprost	Eye drops 0.004%
Hydrocortisone	Crn 1% (pack size greater than 100 g)	Water for Injection	Purified for inj 5 ml
Hydrocortisone	Crn 1% (pack size greater than 15 g and less than 100 g)	Water for Injection	Purified for inj 10 ml
Sodium chloride	Inj 0.9%, 5 ml	Water for Injection	Purified for inj 20 ml
Sodium chloride	Inj 0.9%, 10 ml	Wool fat	Crn
Sodium chloride	Inj 0.9%, 20 ml	Zinc and castor oil	Oint BP (pack size greater than 30 g)

2014/15 Invitation to Tender

Chemical Name	Line Item	Chemical Name	Line Item
Ambrisentan	Tab 5 mg	Propranolol	Tab 10 mg
Ambrisentan	Tab 10 mg	Propranolol	Tab 40 mg
Carboplatin	Inj 10 mg per ml, 100 ml	Single chamber empty IV infusion bags	DEHP-free IV infusion bag, 250 ml
Doxorubicin hydrochloride	Inj 10 mg	Single chamber empty IV infusion bags	DEHP-free IV infusion bag, 500 ml
Enoxaparin sodium	Inj 20 mg per 0.2 ml	Single chamber empty IV infusion bags	DEHP-free IV infusion bag, 1,000 ml
Enoxaparin sodium	Inj 40 mg per 0.4 ml	Single chamber empty IV infusion bags	Latex-free IV infusion bag, 250 ml
Enoxaparin sodium	Inj 60 mg per 0.6 ml	Single chamber empty IV infusion bags	Latex-free IV infusion bag, 500 ml

Chemical Name	Line Item	Chemical Name	Line Item
Enoxaparin sodium	Inj 80 mg per 0.8 ml	Single chamber empty IV infusion bags	Latex-free IV infusion bag, 1,000 ml
Enoxaparin sodium	Inj 100 mg per ml, 1 ml	Single chamber empty IV infusion bags	PVC-free IV infusion bag, 250ml
Enoxaparin sodium	Inj 120 mg per 0.8 ml	Single chamber empty IV infusion bags	PVC-free IV infusion bag, 500 ml
Enoxaparin sodium	Inj 150 mg per ml, 1 ml	Single chamber empty IV infusion bags	PVC-free IV infusion bag, 1,000 ml
Fluorouracil sodium	Inj 50 mg per ml, 10 ml	Single chamber empty IV infusion bags	PVC-free, DEHP-free and latex-free IV infusion bag, 250 ml
Idarubicin Hydrochloride	Cap 5 mg	Single chamber empty IV infusion bags	PVC-free, DEHP-free and latex-free IV infusion bag, 500 ml
Idarubicin Hydrochloride	Cap 10 mg	Single chamber empty IV infusion bags	PVC-free, DEHP-free and latex-free IV infusion bag, 1,000 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 2 ml	Testosterone	Transdermal patch 2.5 mg
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 2 ml	Testosterone	Transdermal patch 5 mg
Mitozantrone	Inj 2 mg per ml, 5 ml	Tobramycin	Inj 100 mg per ml, 5 ml vial
Mitozantrone	Inj 2 mg per ml, 12.5 ml	Tobramycin	Powder BP
Pancreatic enzyme	Cap EC 24,000-25,000 BP u lipase, 22,000-23,000 BP u amylase and 1,000-1,500 BP u protease	Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule
Promethazine Hydrochloride	Inj 25 mg per ml, 2 ml		

For products included in the 2013/14 and 2014/15 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.